A Phase 2 interventional study of Riboflavin and UVX light in Keratoconus and Post-Refractive Ectasia, sponsored by Price Vision Group. Completed at 1 site in United States. Open to participants aged 10 Years and older. Per ClinicalTrials.gov, last updated 2018-06-06.
Sponsored by Price Vision Group · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing riboflavin in Keratoconus — 5 open to participants now, 8 under way, 7 of them phase 3. Riboflavin · Keratoconus.
Among the 23 studies testing riboflavin in Keratoconus, this one is the 3rd largest by enrollment, is one of 6 that started in 2010, is one of 3 in phase 2, and was the 4th registered.
313 studies on the registry are indexed under Keratoconus; 56 are open to participants now.
Browse Keratoconus studies →5 of the 23 studies testing riboflavin in Keratoconus are open now, in 1 country. Recruiting first, the newest first:
Price Vision Group · Sites in United States
Ages 10–90
Cornea and Laser Eye Institute · Sites in United States
Ages 18+ · Healthy volunteers
Cornea and Laser Eye Institute · Sites in United States
Ages 12+ · Healthy volunteers
Cornea and Laser Eye Institute · Sites in United States
Ages 12+ · Healthy volunteers
Kent Wellish MD
Ages 12+
By country, each count listing its studies:
Riboflavin: first FDA approval 1953 (M.V.I.-12 ADULT). What it is approved for, and how studies give it, is on its page →
Of the 37 Keratoconus studies recruiting now, 21 (57%) set no upper age limit and 11 (30%) stop at 75 or younger; 17 take children under 18; 15 take healthy volunteers.
This study: 10 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 16 · Phase 4 1
First in 2008; this study’s year is marked. 6 started in 2010.
This study's enrollment of 510 is above the median of 40 across 205 interventional studies indexed under Keratoconus.
Median enrollment 170 across the 23 interventional studies. Of the 10 that completed or were terminated, 2 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 23 have an industry lead sponsor. The 10 most frequent:
Price Vision Group is the lead sponsor of 11 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Price Vision Group has 3 studies filed under Keratoconus — fewer than ten, so there is no comparison to draw.
1 of the studies testing riboflavin in Keratoconus that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04731727Kent Wellish MDTreating Corneal Thinning Conditions With CCL Vario Riboflavin (CXL) | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies testing riboflavin in Keratoconus, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effectiveness of using riboflavin and UV light to treat progressive keratoconus or post-refractive corneal ectasia.
The primary objective of this study is to evaluate two riboflavin-dosing regimens for corneal collagen cross-linking to slow the progressive changes in corneal curvature in eyes with progressive keratoconus or post-refractive ectasia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Having documented ectasia on topography or tomography after previous refractive surgery OR progressive keratoconus defined as one or more of the following changes over a period of 36 months or less before randomization:
Subjects with keratoconus diagnosis only:
a. Axial topography consistent with keratoconus b. Presence of central or inferior steepening on the Pentacam map. c. Presence of one or more slit lamp findings associated with keratoconus, such as: i. Fleischer ring ii. Vogt striae iii. Corneal thinning iv. Corneal scarring
Contact Lens Wearers Only: Removal of contact lenses for the required period of time prior to the screening refraction:
Contact Lens Type Minimum Discontinuation Time Soft 3 Days Soft Extended Wear 1 Week Soft Toric 2 Weeks Rigid gas permeable 2 Weeks
Exclusion Criteria:
Any keratoconus patient over 21 years of age without evidence of progression of his corneal deformity.
a. History of corneal disease (e.g., herpes simplex, herpes zoster keratitis, recurrent erosion syndrome, corneal melt, corneal dystrophy, etc.) b. corneal scarring in the proposed treatment zone 4. A history of chemical injury or delayed epithelial healing in the eye(s) to be treated.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The eye will be irradiated for 30 minutes with UVX light, during which time instillation of riboflavin will continue (1 drop every 5 minutes for this arm).
Drug: Riboflavin · Device: UVX light
The eye will be irradiated for 30 minutes with UVX light, during which time instillation of riboflavin will continue (1 drop every 2 minutes for this arm).
Drug: Riboflavin · Device: UVX light
Riboflavin 0.1% eye drops are applied before and during irradiation of the cornea.
UVX 365 nm wavelength light source is applied with continued application of riboflavin.
Change in Maximum Keratometry From Baseline to 6 Months After Treatment
Change in maximum keratometry (Kmax) between baseline and 6 months after treatment, measured by corneal tomography.
Time frame: 6 months
Pachymetry
Minimum corneal thickness measured by corneal tomography
Time frame: 6 months
Corrected Distance Visual Acuity (CDVA)
Corrected distance visual acuity (CDVA) reported in logarithm of the minimum angle of resolution (logMAR). Lower numbers represent better vision; 0.0 corresponds to 20/20 vision. Each increase of 0.1 on the logMAR scale corresponds to one less line read on the eye chart.
Time frame: 6 months
Uncorrected Distance Visual Acuity (UDVA)
Uncorrected distance visual acuity reported in logarithm of the minimum angle of resolution units. Lower numbers represent better vision; 0.0 corresponds to 20/20 vision without any type of correction such as glasses. Each increase of 0.1 on the logMAR scale corresponds to one less line read on the eye chart.
Time frame: 6 months
| Milestone | Riboflavin 0.1% Eyedrops Every 5 Minutes | Riboflavin 0.1% Eyedrops Every 2 Minutes |
|---|---|---|
| Started | 253 | 257 |
| Completed | 227 | 232 |
| Not completed | 26 | 25 |
| Withdrew: Lost to follow-up | 26 | 25 |
Change in maximum keratometry (Kmax) between baseline and 6 months after treatment, measured by corneal tomography.
| diopters | Riboflavin 0.1% Eyedrops Every 5 Minutes | Riboflavin 0.1% Eyedrops Every 2 Minutes |
|---|---|---|
| Change in Maximum Keratometry From Baseline to 6 Months After Treatment | 0.76 ± 2.4 | 0.97 ± 3.2 |
Minimum corneal thickness measured by corneal tomography
| microns | Riboflavin 0.1% Eyedrops Every 5 Minutes | Riboflavin 0.1% Eyedrops Every 2 Minutes |
|---|---|---|
| Pachymetry | 438 ± 51 | 434 ± 20 |
Corrected distance visual acuity (CDVA) reported in logarithm of the minimum angle of resolution (logMAR). Lower numbers represent better vision; 0.0 corresponds to 20/20 vision. Each increase of 0.1 on the logMAR scale corresponds to one less line read on the eye chart.
| logMAR | Riboflavin 0.1% Eyedrops Every 5 Minutes | Riboflavin 0.1% Eyedrops Every 2 Minutes |
|---|---|---|
| Corrected Distance Visual Acuity (CDVA) | 0.32 ± 0.29 | 0.31 ± 0.28 |
Uncorrected distance visual acuity reported in logarithm of the minimum angle of resolution units. Lower numbers represent better vision; 0.0 corresponds to 20/20 vision without any type of correction such as glasses. Each increase of 0.1 on the logMAR scale corresponds to one less line read on the eye chart.
| logMAR | Riboflavin 0.1% Eyedrops Every 5 Minutes | Riboflavin 0.1% Eyedrops Every 2 Minutes |
|---|---|---|
| Uncorrected Distance Visual Acuity (UDVA) | 0.95 ± 0.53 | 0.91 ± 0.55 |
Collected over 6 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Riboflavin 0.1% Eyedrops Every 5 Minutes | 0/253 (0%) | 0/253 (0%) | 12/253 (4.7%) |
| Riboflavin 0.1% Eyedrops Every 2 Minutes | 0/257 (0%) | 0/257 (0%) | 13/257 (5.1%) |
| Event | Riboflavin 0.1% Eyedrops Every 5 Minutes | Riboflavin 0.1% Eyedrops Every 2 Minutes |
|---|---|---|
| Loss of 2 or more logMAR lines of corrected distance visual acuity (CDVA) relative to baselineEye disorders | 12/253 | 13/257 |
| Age, Continuous(years) | Riboflavin 0.1% Eyedrops Every 5 Minutes | Riboflavin 0.1% Eyedrops Every 2 Minutes | Total |
|---|---|---|---|
| Mean | 32 ± 12 | 32 ± 13 | 32 ± 13 |
| Sex: Female, Male(Participants) | Riboflavin 0.1% Eyedrops Every 5 Minutes | Riboflavin 0.1% Eyedrops Every 2 Minutes | Total |
|---|---|---|---|
| Female | 62 | 61 | 123 |
| Male | 191 | 196 | 387 |
| Race (NIH/OMB)(Participants) | Riboflavin 0.1% Eyedrops Every 5 Minutes | Riboflavin 0.1% Eyedrops Every 2 Minutes | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 10 | 13 | 23 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 28 | 24 | 52 |
| White | 215 | 220 | 435 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Riboflavin 0.1% Eyedrops Every 5 Minutes | Riboflavin 0.1% Eyedrops Every 2 Minutes | Total |
|---|---|---|---|
| United States | 253 | 257 | 510 |
| Keratoconus/ectasia classification(Participants) | Riboflavin 0.1% Eyedrops Every 5 Minutes | Riboflavin 0.1% Eyedrops Every 2 Minutes | Total |
|---|---|---|---|
| Keratoconus mild (flat K <51D and astigmatism <8D) | 140 | 139 | 279 |
| Keratoconus moderate | 43 | 43 | 86 |
| Keratoconus severe (flat K >56D by tomography) | 20 | 21 | 41 |
| Ectasia after refractive surgery | 50 | 54 | 104 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of May 2010, a primary completion of May 2017 and a completion of Aug 2017. It does not say whether these dates are actual or estimated.
Results were first posted in May 2018, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Riboflavin
Price Vision Group